Clinical trials: Multiple Sclerosis Spasticity
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
This clinical research study is investigating whether the EXOPULSE Suit, a wearable device that delivers electrical stimulation, can help improve movement difficulties caused by spasticity in adults with multiple sclerosis (MS).
- Trial name
- EXO-MS (NCT07897760)
- Testing
- Electrostimulation suit
- Where
- 2 sites in United States, Germany
- Volunteers
- 100 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Multiple Sclerosis, Relapsing Remitting
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity…
- Trial name
- NCT01080040
- Where
- Argentina
- Volunteers
- 150 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Spasticity
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period…
- Trial name
- NCT01964547
- Testing
- Sativex
- Where
- Czechia
- Volunteers
- 121 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
The study is a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS).
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain, Chronic
- Trial name
- FO-NP002 (NCT05562453)
- Testing
- FlowOx 2.0
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- Otivio AS
Spasticity Due to Multiple Sclerosis
BX-1 in Spasticity Due to Multiple Sclerosis
To investigate the efficacy and safety of orally administered BX-1 compared to placebo in patients with spasticity due to multiple sclerosis not sufficiently controlled by current anti-spasticity medication
- Trial name
- NCT03756974
- Testing
- BX-1
- Where
- 40 sites in Czechia, Germany and 3 more
- Volunteers
- 397 people
- Sponsor
- Bionorica SE
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Spasticity
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity.
- Trial name
- NCT05179577
- Testing
- Arbaclofen
- Volunteers
- 442 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).
- Trial name
- NCT04990219
- Testing
- Lu AG06466
- Where
- 7 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- H. Lundbeck A/S
Multiple Sclerosis, Spasticity, Muscle
Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity
This is a descriptive, prospective, non-controlled clinical investigation to be conducted on approximately 10 enrolled subjects at one site at Haukeland University Hospital in Bergen, Norway.
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain
- Trial name
- FlowOx-MS (NCT04904016)
- Testing
- FlowOx™
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Otivio AS
Spasticity, Cerebrovascular Accident
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension…
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury
- Trial name
- NCT04815967
- Testing
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 32 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Muscle Spasticity Due to Multiple Sclerosis
Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis
To evaluate efficacy and safety of BGG492 versus placebo on moderate to severe spasticity due to multiple sclerosis
- Trial name
- NCT01649050
- Testing
- BGG492
- Sponsor
- Novartis Pharmaceuticals
Muscle Spasticity
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following…
- Trial name
- NCT00358293
- Testing
- Tizanidine (sublingual or oral)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Teva GTC
Muscle Spasticity
Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis
A drug called AV650 (tolperisone HCl) will be given to patients who have spasticity associated with multiple sclerosis. This study has three purposes: 1. To determine whether AV650 is safe for patients with multiple sclerosis; 2.
- Trial name
- NCT00532532
- Testing
- tolperisone HCl
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 150 people
- Sponsor
- Avigen
Spasticity
Study of SPARC1103 in Subjects With Spasticity
Study of SPARC1103 in subjects with spasticity
- Trial name
- NCT02027025
- Testing
- SPARC1103 low dose, SPARC1103 high dose
- Where
- 23 sites in United States, Russia and 1 more
- Volunteers
- 142 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd